BioCentury | Aug 1, 2020
Management Tracks

Nabel leaves Moderna’s board to avoid conflict-of-interest concerns; plus changes at Genespire, La Jolla, Editas and more

mRNA company Moderna Inc. (NASDAQ:MRNA) said Elizabeth Nabel has resigned from its board to avoid any potential or apparent conflict of interest. She is president of Brigham and Women’s Hospital, a site enrolling patients in...
BioCentury | Mar 1, 2019
Company News

In latest deal, AbbVie and Voyager seek vectorized antibodies for Parkinson's

AbbVie Inc. (NYSE:ABBV) is expanding its gene therapy footprint through a deal with Voyager Therapeutics Inc. (NASDAQ:VYGR) to develop vectorized antibodies that can cross the blood-brain barrier to target α-synuclein to treat Parkinson's disease. Voyager...
BioCentury | Mar 1, 2019
Financial News

After J&J retinal dea, MeiraGTx raises $80M for partnered programs

MeiraGTx Holdings plc (NASDAQ:MGTX) added $2.23 (17%) to $15.50 on Feb. 27 after the company raised $80 million in a private placement, which includes a $40 million equity investment from Johnson & Johnson Innovation - JJDC...
BioCentury | Feb 27, 2019
Financial News

After J&J retinal deal, MeiraGTx raises $80M for unpartnered programs

MeiraGTx Holdings plc (NASDAQ:MGTX) added $2.23 (17%) to $15.50 on Wednesday after the company raised $80 million in a private placement, which includes a $40 million equity investment from Johnson & Johnson Innovation - JJDC Inc....
BioCentury | Feb 23, 2019
Company News

In latest deal, AbbVie and Voyager seek vectorized antibodies for Parkinson's

AbbVie Inc. (NYSE:ABBV) is expanding its gene therapy footprint through a deal with Voyager Therapeutics Inc. (NASDAQ:VYGR) to develop vectorized antibodies that can cross the blood-brain barrier to target α-synuclein to treat Parkinson's disease. Voyager...
BioCentury | Oct 10, 2018
Company News

Management tracks: Hamburg joins Alnylam board

RNAi therapeutics company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) appointed Margaret Hamburg to its board, effective Jan. 10, 2019. Hamburg is president-elect of the American Association for the Advancement of Science (AAAS), foreign secretary of the National...
BioCentury | Aug 31, 2018
Financial News

Y-mAbs aims for $92M IPO

Y-mAbs Therapeutics Inc. (New York, N.Y.) filed to raise up to $92 million on Aug. 24 in an IPO on NASDAQ underwritten by BofA Merrill Lynch, Cowen, Canaccord Genuity and BTIG. Y-mAbs hopes to submit...
BioCentury | Aug 24, 2018
Financial News

Y-mAbs aiming for $92M IPO

Y-mAbs Therapeutics Inc. (New York, N.Y.) filed to raise up to $92 million in an IPO on NASDAQ underwritten by BofA Merrill Lynch, Cowen, Canaccord Genuity and BTIG. Y-mAbs hopes to submit BLAs next year...
BioCentury | Jul 13, 2018
Clinical News

Janssen's esketamine meets in Phase III to prevent treatment-resistant depression relapse

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) said intranasal esketamine (formerly JNJ-54135419) plus an oral antidepressant met the primary endpoint of delaying time to relapse during maintenance treatment compared with an oral...
BioCentury | Jul 10, 2018
Distillery Therapeutics

Cancer

INDICATION: Small cell lung cancer Patient sample and cell culture studies suggest promoting IGFBP5 expression or inhibiting POU2F3 or IGF1R could help treat POU2F3-expressing small cell lung cancer (SCLC). In tumor samples from SCLC patients,...
Items per page:
1 - 10 of 434